AnaptysBio, Inc.
imsidolimab
generalized pustular psoriasis (GPP)
Countdown
158days
FDA decision · Dec 12, 2026
What's at stake
The FDA's approval decision on imsidolimab for generalized pustular psoriasis (GPP) is due Dec 12, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“FDA target action date (PDUFA) of Dec. 12, 2026 for imsidolimab in generalized pustular psoriasis (GPP)”